STOCK TITAN

Avalyn Pharma officer proposes $1.58M stock sale

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
144

Rhea-AI Filing Summary

Avalyn Pharma Inc. (AVLN) officer Howard Lazarus reported a proposed sale of 53,200 common shares, with an aggregate market value of $1,583,232 and an approximate sale date of November 17, 2026. Lazarus's remarks state that the shares were and will be received upon exercise of stock options over the next three months, and list July 30, 2026, as the Rule 10b5-1 plan adoption date.

Common shares proposed for sale 53,200 shares Approximate sale date: November 17, 2026
Aggregate market value $1,583,232 Proposed sale of common shares
Common shares outstanding 44,521,494 shares Listed in the securities information
Rule 10b5-1 plan adoption date July 30, 2026 Date listed for plan adoption
Rule 10b5-1 regulatory
"Date of Plan Adoption or Giving of Instruction"
Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.
Exercise of Stock Options financial
"Nature of Acquisition Transaction"
Aggregate Market Value financial
"Aggregate Market Value"
Aggregate market value is the combined price you would pay to buy all outstanding shares of a company or all companies in a group at current market prices — essentially the sum of each stock’s market capitalization. It matters to investors because it shows the overall size and weight of an investment or sector (like the total cost to buy every piece of a puzzle), helps compare scale across companies or markets, and influences index composition and risk exposure.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many AVLN shares did Howard Lazarus propose to sell?

Howard Lazarus reported a proposed sale of 53,200 Avalyn Pharma common shares, with an aggregate market value of $1,583,232. The approximate sale date is November 17, 2026.

Is Howard Lazarus's proposed AVLN sale tied to a Rule 10b5-1 plan?

The notice lists July 30, 2026, as the Rule 10b5-1 plan adoption date. The shares to be sold were and will be received upon exercise of stock options over the next three months.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

Keep reading